BMPR2 and pulmonary arterial hypertension: Additionally, administration of low-dose tacrolimus restored signaling through the BMPR2, and reversed severe PAH in the MCT-induced model and in the VEGF receptor blockade/chronic hypoxia model, suggesting potential clinical benefit with low-dose therapy [135].